These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 24241366)

  • 1. Effectiveness of haemodiafiltration with ultrafiltrate regeneration in the reduction of light chains in multiple myeloma with renal failure.
    Pendón-Ruiz de Mier MV; Alvarez-Lara MA; Ojeda-López R; Martín-Malo A; Carracedo J; Caballero-Villarraso J; Alonso C; Aljama P
    Nefrologia; 2013 Nov; 33(6):788-96. PubMed ID: 24241366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemodiafiltration with ultrafiltrate regeneration reduces free light chains without albumin loss in multiple myeloma patients.
    Pendón-Ruiz de Mier MV; Ojeda R; Álvarez-Lara MA; Navas A; Alonso C; Caballero-Villarraso J; Aljama P; Álvarez MA; Soriano S; Rodríguez M; Martín-Malo A
    BMC Nephrol; 2020 Jun; 21(1):227. PubMed ID: 32539688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum Free Light Chains Removal by HFR Hemodiafiltration in Patients with Multiple Myeloma and Acute Kidney Injury: a Case Series.
    Menè P; Giammarioli E; Fofi C; Antolino G; Verde G; Tafuri A; Punzo G; Festuccia F
    Kidney Blood Press Res; 2018; 43(4):1263-1272. PubMed ID: 30078004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of blood purification and bortezomib plus dexamethasone therapy for the treatment of acute renal failure due to myeloma cast nephropathy.
    Hasegawa M; Kondo F; Yamamoto K; Murakami K; Tomita M; Nabeshima K; Nakai S; Kato M; Ohashi A; Arai J; Hiki Y; Ishii J; Emi N; Sugiyama S; Yuzawa Y
    Ther Apher Dial; 2010 Oct; 14(5):451-6. PubMed ID: 21175542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of Haemodiafiltration with Heat Sterilized High-Flux Polyphenylene HF Dialyzer in Reducing Free Light Chains in Patients with Myeloma Cast Nephropathy.
    Rousseau-Gagnon M; Agharazii M; De Serres SA; Desmeules S
    PLoS One; 2015; 10(10):e0140463. PubMed ID: 26466100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloma kidney: the importance of assessing the response by monitoring free light chains in serum.
    Martín-Gómez MA; García-Marcos SA; Caba-Molina M; Palacios-Gómez ME; Gómez-Morales M; Claver-Ferré C
    Nefrologia; 2013 Nov; 33(6):862-4. PubMed ID: 24241381
    [No Abstract]   [Full Text] [Related]  

  • 7. A novel option for reducing free light chains in myeloma kidney: supra-hemodiafiltration with endogenous reinfusion (HFR).
    Pasquali S; Iannuzzella F; Corradini M; Mattei S; Bovino A; Stefani A; Palladino G; Caiazzo M
    J Nephrol; 2015 Apr; 28(2):251-4. PubMed ID: 25149172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis.
    Hutchison CA; Heyne N; Airia P; Schindler R; Zickler D; Cook M; Cockwell P; Grima D
    Nephrol Dial Transplant; 2012 Oct; 27(10):3823-8. PubMed ID: 22273664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy of SUPRA HFR in the treatment of acute renal damage during multiple myeloma].
    Daidola G; Guarena C; Brustia M; Leonardi G; Vigotti FN; Marciello A; Bianco S; Chiarinotti D; Saltarelli M; Besso L; Biancone L
    G Ital Nefrol; 2018 Dec; 35(6):. PubMed ID: 30550040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of free light chain removal by four blood purification methods.
    Kanayama K; Ohashi A; Hasegawa M; Kondo F; Yamamoto Y; Sasaki M; Hayashi H; Kato M; Hattori R; Yamashita H; Arai J; Ishii J; Emi N; Yuzawa Y
    Ther Apher Dial; 2011 Aug; 15(4):394-9. PubMed ID: 21884475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Online high-efficiency haemodiafiltration achieves higher serum free light chain removal than high-flux haemodialysis in multiple myeloma patients: preliminary quantitative study.
    Granger Vallée A; Chenine L; Leray-Moragues H; Patrier L; Cognot C; Cartron G; Cristol JP; Canaud B
    Nephrol Dial Transplant; 2011 Nov; 26(11):3627-33. PubMed ID: 21508098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experience of using hemodialysis with medium cut-off dialyzer in cast nephropathy.
    Cazorla López JM; García García-Doncel A; Naranjo Muñoz J; Villanego Fernández F; Vigara Sánchez LA; Ceballos Guerrero M
    Nefrologia (Engl Ed); 2020; 40(3):367-369. PubMed ID: 32007298
    [No Abstract]   [Full Text] [Related]  

  • 13. Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents.
    Mori S; Crawford BS; Roddy JV; Phillips G; Elder P; Hofmeister CC; Efebera Y; Benson DM
    Hematol Oncol; 2012 Sep; 30(3):156-62. PubMed ID: 22028144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Partial recovery of kidney function for an autologous transplant in a patient with chronic kidney disease and multiple myeloma].
    de Alarcón Jiménez RM; Roca Meroño S; Alvarez Fernández GM; García Hernández MA; Navarro Parreño MJ; Jimeno Griñó C; Zarco Pedrinaci E; Molina Núñez M
    Nefrologia; 2011; 31(2):238-40. PubMed ID: 21461027
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR.
    Hansen CT; Pedersen PT; Nielsen LC; Abildgaard N
    Eur J Haematol; 2014 Nov; 93(5):407-13. PubMed ID: 24809596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment by long haemodialysis sessions with high cut-off filters in myeloma cast nephropathy: our experience.
    Borrego-Hinojosa J; Pérez-del Barrio MP; Biechy-Baldan Mdel M; Merino-García E; Sánchez-Perales MC; García-Cortés MJ; Ocaña-Pérez E; Gutiérrez-Rivas P; Liébana-Cañada A
    Nefrologia; 2013; 33(4):515-23. PubMed ID: 23897183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haemodialysis using high cut-off dialysers for treating acute renal failure in multiple myeloma.
    Martín-Reyes G; Toledo-Rojas R; Torres-de Rueda Á; Sola-Moyano E; Blanca-Martos L; Fuentes-Sánchez L; Martínez-Esteban MD; Díez-de los Ríos MJ; Bailén-García A; González-Molina M; García-González I
    Nefrologia; 2012; 32(1):35-43. PubMed ID: 22294003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended high cut-off haemodialysis for myeloma cast nephropathy in Auckland, 2008-2012.
    Tan J; Lam-Po-Tang M; Hutchison CA; de Zoysa JR
    Nephrology (Carlton); 2014 Jul; 19(7):432-5. PubMed ID: 24931113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of acute kidney injury in frail patients with biopsy-proven cast nephropathy: a combined approach with chemotherapy plus Supra-hemodiafiltration with post-adsorption endogenous reinfusion.
    Murgia S; Quattrocchio G; Forneris G; Pozzato M; Fenoglio R; Ferro M; De Simone E; Del Vecchio G; Di Benedetto C; Roccatello D
    J Nephrol; 2022 May; 35(4):1243-1249. PubMed ID: 34982413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum free-light chain removal by high cutoff hemodialysis: optimizing removal and supportive care.
    Hutchison CA; Harding S; Mead G; Goehl H; Storr M; Bradwell A; Cockwell P
    Artif Organs; 2008 Dec; 32(12):910-7. PubMed ID: 19133018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.